Beech Hill Advisors’s Takeda Pharmaceutical TAK Stock Holding History

Beech Hill Advisors’s Portfolio TAK Stock Details TAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-26,000	Closed	-$426K	–	95
2021 Q3	$426K	Sell	26,000 -8,000	-24%	-$134K	0.18%	77
2021 Q2	$572K	Sell	34,000 -2,000	-6%	-$34K	0.23%	69
2021 Q1	$657K	Buy	+36,000	New	+$648K	0.27%	63

Other funds holding TAK

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

BCP

BSN Capital Partners London, United Kingdom $3.93B AUM 13.09% 1-Year Est. Return

MIP

Mondrian Investment Partners London, United Kingdom $6.69B AUM

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

PPA

Parametric Portfolio Associates Seattle, Washington $190B AUM 18.52% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Beech Hill Advisors's TAK Position: Q4 2021 in Review

Beech Hill Advisors sold out of Takeda Pharmaceutical (TAK) in Q4 2021, closing a stake of 26,000 shares — an estimated $426K sold.

Beech Hill Advisors first reported a position in TAK in Q1 2021 and held it in 3 quarters. The position peaked at $657K in Q1 2021. 298 funds tracked by Wall St. Rank hold TAK as of Q4 2021.

Beech Hill Advisors reported no remaining Takeda Pharmaceutical position as of Q4 2021 after selling out during the quarter.
Beech Hill Advisors sold 26,000 Takeda Pharmaceutical shares in Q4 2021, an estimated $426K.
Beech Hill Advisors first reported a position in Takeda Pharmaceutical in Q1 2021 and held it in 3 quarters.
Beech Hill Advisors's Takeda Pharmaceutical position peaked at $657K in Q1 2021.
298 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q4 2021.

Based on Beech Hill Advisors's 13F filing for Q4 2021, filed 19 Jan 2022.